DUBLIN--(BUSINESS WIRE)--The "Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis Report By Type of Synthesis (Biotech, Synthetic), By Type of Manufacturer (Captive, Merchant), By Application, By Region, And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
The global active pharmaceutical ingredient (API) market size is expected to reach at USD 268.12 billion by 2026 registering a CAGR of 6.8%
Rising trend of outsourcing APIs and growing prevalence of various target diseases, such as cancer, Cardiovascular Disease (CVDs) are anticipated to boost the market. Huge capital is required in API production as the process needs extremely systematic protocols. Pharmaceutical companies can actually benefit from outsourcing API production, as it eliminates the need for installing expensive manufacturing units. Moreover, strategic outsourcing enables companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also estimated to drive the demand in future.
Growing geriatric population across the globe is also likely to contribute to the market expansion. Estimates published by the WHO suggest that the global base of population pertaining to the age group of 65 years and above is expected to rise from 7% in 2000 to 16% in 2050. Latin America, in particular, is projected to witness fastest growth, in terms of geriatric population, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).
Patent expiration of blockbuster drugs, growing outsourcing activities due to high manufacturing costs, and stringent regulations for API production are expected to intensify the market competition. As part of strategic geographic expansion, many companies are setting up manufacturing plants in the developing regions like Asia Pacific.
Further key findings from the study suggest:
- Synthetic APIs held the largest share of the API market in 2018 owing to easy availability of raw materials and easier protocols for synthesis of these molecules
- Biotech APIs are estimated to register the highest CAGR over the forecast years due to rising demand for biopharmaceuticals and higher efficiency of these molecules
- Captive manufacturers led the market owing to intensive capitalization of major key players in development of high-end manufacturing facilities
- Merchant manufacturers segment is expected to be the fastest-growing segment over the forecast period
- Generic APIs are expected to register a lucrative CAGR over the forecast period on account of factors, such as expiration of patents of branded drugs and lower cost
- Cardiology segment led the overall market in 2018. Increasing prevalence of target diseases worldwide and high demand for fast-acting drugs are some of the key factors responsible for the segment growth
- North America held the largest market share in 2018. Asia Pacific is estimated to be the fastest-growing region expanding at a CAGR of 8.2% over the estimated period
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 API Market Outlook
2.2 API Market: Segment Outlook
2.3 API Market: Competitive Insights
2.4 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration and Growth Prospect Mapping
Chapter 4 Market Dynamics
4.1 Market Driver Analysis
4.1.1 Growing Geriatric Population Base
4.1.2 Growing Prevalence Of Target Diseases Such As Hospital Acquired Infections, Genetic, Cardiovascular And Neurological Diseases
4.1.3 Increasing Preference For Targeted Therapy Approach In Cancer Treatment
4.1.4 Increasing Preference For Outsourcing APIs
4.2 Market Restraint Analysis
4.2.1 Large Capital Investments And Production Cost
4.2.2 Stringent Safety And Handling Regulations Regarding APIs
Chapter 5 API Market Analysis Tools
5.1 Industry Analysis - Porter's
5.2 PESTEL Analysis
5.3 Major Deals & Strategic Alliances Analysis
Chapter 6 API Market - Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
6.3 Public Companies
6.4 Private Companies
Chapter 7 API Molecules Outlook
7.1 Global Sales (2014 - 2017)
7.2 Companies With Leading Market Position For API Molecules
7.2.1 Amoxicillin
7.2.2 Azithromycin
7.2.3 Bleomycin
7.2.4 Caspofungin
7.2.5 Clarithromycin
7.2.6 Clavulanic Acid
7.2.7 Clindamycin
7.2.8 Compactin (Mevastatin)
7.2.9 Cyclosporin
7.2.10 Dactinomycin
7.2.11 Daptomycin
7.2.12 Demeclocycline
7.2.13 Doxycycline
7.2.14 Erythromycin
7.2.15 Ivermectin (Avermectin)
7.2.16 Lovastatin
7.2.17 Micafungin
7.2.18 Minocycline
7.2.19 Mitomycin
7.2.20 Mycophenolic Acid
7.2.21 Pneumocandin B0
7.2.22 Polymyxin
7.2.23 Pravastatin
7.2.24 Rapamycin (Sirolimus)
7.2.25 Simvastatin
7.2.26 Steroids
7.2.27 Tacrolimus
7.2.28 Tetracycline
7.2.29 Tigecycline
7.2.30 Tobramycin
7.2.31 Vancomycin
7.3 Comparative Price Analysis Of The Above-Mentioned Molecules
Chapter 8 Type Of Synthesis Business Analysis
8.1. Definitions & Scope
8.2. Type of Synthesis Market Share Analysis, 2018 & 2026
8.3. API Market, by Type of Synthesis, 2014 to 2026
8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
8.5 Biotech API
8.5.1 Biotech API Market, 2014 - 2026 (USD Billion)
8.5.2 Monoclonal Antibodies
8.5.3 Recombinant Proteins
8.5.4 Vaccines
8.6 Synthetic API
Chapter 9 Type Of Manufacturer Business Analysis
9.1. Definitions & Scope
9.2. Type of Manufacturer Market Share Analysis, 2018 & 2026
9.3. API Market, by Type of Manufacturer, 2014 to 2026
9.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
9.5 Captive API
9.6 Merchant API
Chapter 10 Type Business Analysis
10.1. Definitions & Scope
10.2. Type Market Share Analysis, 2018 & 2026
10.3. API Market, by Type, 2014 to 2026
10.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
10.5 Generic APIs
10.6 Innovative APIs
Chapter 11 Application Business Analysis
11.1. Definitions & Scope
11.2. Application Market Share Analysis, 2018 & 2026
11.3. API Market, by Application, 2014 to 2026
11.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
11.5 Cardiology
11.6 Oncology
11.7 Cns & Neurology
11.8 Orthopedics
11.9 Endocrinology
11.10 Pulmonology
11.11 Gastroenterology
11.12 Nephrology
11.13 Ophthalmology
11.14 Others
Chapter 12 Application, By Type Business Analysis (Cross-Matrix)
12.1. Definitions & Scope
12.2. Application Market Share Analysis, 2018 & 2026
12.3. API Market, by Application, 2014 to 2026
12.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
12.5 Cardiology
12.6 Oncology
12.7 CNS & Neurology
12.8 Orthopedics
12.9 Endocrinology
12.10 Pulmonology
12.11 Gastroenterology
12.12 Nephrology
12.13 Ophthalmology
12.14 Others
Chapter 13 API Market: Regional Estimates & Trend Analysis
Chapter 14 Competitive Landscape
- Abbvie, Inc.
- Boehringer Ingelheim International Gmbh
- Bristol-Myers Squibb Company
- Cipla Inc.
- Merck & Co., Inc.
- Albemarle Corporation
- Aurobindo Pharma
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries, Ltd.
- Dr. Reddy'S Laboratories Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/pg6eku
